EP4574811A1 — Crystalline forms of elacestrant dihydrochloride
Assigned to Sandoz AG · Expires 2025-06-25 · 1y expired
What this patent protects
The present invention relates to novel crystalline forms of Elacestrant dihydrochloride. The present disclosure also generally relates to a pharmaceutical composition comprising the crystalline forms of Elacestrant dihydrochloride of the present invention, as well of methods of u…
USPTO Abstract
The present invention relates to novel crystalline forms of Elacestrant dihydrochloride. The present disclosure also generally relates to a pharmaceutical composition comprising the crystalline forms of Elacestrant dihydrochloride of the present invention, as well of methods of using the same in the treatment of conditions and diseases driven by estrogen, preferably for the treatment of breast cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.